Compare BWMX & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMX | DBVT |
|---|---|---|
| Founded | 1995 | 2002 |
| Country | Mexico | France |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.6M | 508.8M |
| IPO Year | N/A | N/A |
| Metric | BWMX | DBVT |
|---|---|---|
| Price | $14.06 | $21.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $22.50 | ★ $31.75 |
| AVG Volume (30 Days) | 27.8K | ★ 659.6K |
| Earning Date | 10-23-2025 | 10-28-2025 |
| Dividend Yield | ★ 10.62% | N/A |
| EPS Growth | ★ 15.49 | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $775,128,445.00 | $5,502,000.00 |
| Revenue This Year | $3.50 | $1,768.71 |
| Revenue Next Year | $5.30 | $1,028.88 |
| P/E Ratio | $9.41 | ★ N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $7.00 | $2.74 |
| 52 Week High | $15.00 | $26.19 |
| Indicator | BWMX | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 69.38 |
| Support Level | $13.85 | $17.50 |
| Resistance Level | $14.69 | $26.19 |
| Average True Range (ATR) | 0.44 | 1.62 |
| MACD | -0.05 | 0.68 |
| Stochastic Oscillator | 36.09 | 62.56 |
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.